Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Jaguar Health (NASDAQ: JAGX) family company Napo announced acceptance of two late-breaking abstracts at ESPGHAN for liquid oral crofelemer treating pediatric intestinal failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS).

Rhea-AI Summary

Jaguar Health (NASDAQ: JAGX) family company Napo announced acceptance of two late-breaking abstracts at ESPGHAN for liquid oral crofelemer treating pediatric intestinal failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS).

Company reports crofelemer was well tolerated, associated with reductions in parenteral support (PS) and gains in weight/height in treated pediatric patients; orphan drug designations exist in the US and EU and a pediatric randomized MVID trial completed enrollment with an NDA planned mid-2027.

Positive

• Two late-breaking abstracts accepted for ESPGHAN presentation
• Orphan drug designations for MVID and SBS in US and EU
• Completed enrollment of pediatric MVID randomized trial; NDA planned mid-2027
• Reported reductions in parenteral support needs in treated pediatric IF patients
• Crofelemer described as well tolerated with patient weight and height gains

Negative

• Crofelemer currently used in approximately 4% of prevalent MVID patients
• Clinical evidence comes from investigator-initiated and ongoing trials, not yet regulatory approval
• Parenteral support remains required for patients; reductions reported but not elimination of PS

Argus Apr 24 session

-1.67% close to close Open Argus

Details

News Market Reaction – JAGX

On Apr 24, the day this news came out, JAGX closed 1.67% below the previous close.

Data tracked by StockTitan Argus for the Apr 24 session.

Market Context

This announcement highlights continued development of crofelemer for pediatric intestinal failure du...

Analysis

This announcement highlights continued development of crofelemer for pediatric intestinal failure due to MVID and SBS, including two late-breaking abstracts at the 58th ESPGHAN meeting and plans for an NDA filing in mid-2027. Reported reductions in parenteral support needs and growth improvements support the rare-disease strategy, reinforced by orphan drug designations. Investors may track progression of the pediatric trial, enrollment in adult SBS-IF studies in Europe and the US, and how future financings interact with this development path.

Key Figures

MVID prevalence: approximately 200 patients Crofelemer use in MVID: approximately 4% ESPGHAN meeting: 58th Annual Meeting +5 more

MVID prevalence

approximately 200 patients

Estimated global prevalence of microvillus inclusion disease

Crofelemer use in MVID

approximately 4%

Share of prevalent MVID patients currently treated with crofelemer

ESPGHAN meeting

58th Annual Meeting

Conference where two late-breaking abstracts were accepted

MVID trial timing

mid-2027

Planned NDA filing timing for pediatric MVID trial

Infant treatment duration

more than 6 months

Adjunctive crofelemer therapy duration for one infant MVID IF patient

Pediatric treatment duration

over 1 year

Adjunctive crofelemer therapy duration for other pediatric IF patients

PS frequency

up to 7 days per week

Typical frequency of parenteral support for intestinal failure patients

PS daily duration

20 hours or more per day

Typical daily duration of parenteral support for intestinal failure patients

Historical Context

5 past events · Latest: Apr 20

5 events

1. Apr 20

   Special meeting results

   24h Move

   -0.8%

   All five stockholder proposals approved at the April 2026 special meeting.

2. Apr 13

   AI program support

   24h Move

   +5.7%

   Plans to use AI platforms to enhance crofelemer IF development and commercialization.

3. Apr 09

   Earnings webcast notice

   24h Move

   -2.6%

   Announcement of investor webcast to discuss Q4 2025 financials and updates.

4. Apr 08

   CID trial milestone

   24h Move

   -2.6%

   Completion of Canalevia-CA1 effectiveness study for chemotherapy-induced diarrhea in dogs.

5. Apr 07

   2025 financial results

   24h Move

   -0.1%

   Reported higher operating losses and net loss alongside modest revenue trends.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

orphan drug designations, nda, intestinal failure, microvillus inclusion disease, +4 more

8 terms

orphan drug designations regulatory

"Jaguar has received orphan drug designations for MVID & SBS in the US and EU"

A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.

nda regulatory

"ongoing randomized clinical trial with plans for an NDA filing in mid-2027"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

intestinal failure medical

"Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy"

Intestinal failure is a medical condition in which the gut cannot absorb enough nutrients, fluids, or electrolytes to keep a person healthy, so they need long‑term medical support such as intravenous nutrition or specialized feeding tubes. Think of the intestines as a conveyor belt that breaks down and delivers fuel to the body; when it fails, ongoing treatments, surgeries, and chronic care services become necessary. For investors, this creates steady demand for therapies, medical devices, home infusion services and related regulatory approvals that can drive revenue and long‑term contracts.

microvillus inclusion disease medical

"ultrarare congenital enteropathy due to microvillus inclusion disease (MVID)"

A rare, inherited condition in which the tiny, brush-like hairs on the inner lining of the small intestine are absent or abnormal, causing severe, lifelong diarrhea and inability to absorb nutrients. Think of the intestine’s surface as a shaggy carpet that helps soak up food; when those fibers are missing or disorganized, patients often need long-term intravenous feeding and specialized care. For investors, the disease matters because it creates clear demand for diagnostics, nutritional support, transplant solutions, and targeted therapies in the orphan-disease market.

short bowel syndrome medical

"ultrarare congenital enteropathy due to MVID and/or short bowel syndrome (SBS)"

A chronic digestive disorder caused when a large portion of the small intestine is missing or not working, so the body cannot absorb enough nutrients and fluids from food. Investors should care because people with this condition often need long-term medical treatments, specialized nutrition or surgeries, and ongoing devices or drugs, creating sustained demand, higher healthcare costs, and opportunities for companies that provide therapies, supplies, or related services.

total parenteral nutrition medical

"lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids"

Total parenteral nutrition is a medical treatment that supplies all needed calories, fluids, vitamins and minerals directly into a patient’s bloodstream through an IV, bypassing the digestive tract — like a complete meal delivered by a drip. It matters to investors because TPN relies on specialized ingredients, preparation and delivery services with steady hospital and home-care demand, significant regulation and reimbursement exposure, and potential for durable revenue or risk from supply-chain or clinical issues.

parenteral support medical

"received crofelemer adjunctive therapy for over 1 year together with reduced amounts of parenteral support (PS)"

Parenteral support is medical care that delivers nutrition, fluids or medications directly into a patient’s bloodstream or body tissues, bypassing the digestive system—think of it as feeding or hydrating someone through an IV rather than by mouth. Investors care because this service involves specialized products, durable revenue from long-term patient use, strict safety and reimbursement rules, and potential regulatory or supply risks that affect company earnings and growth.

double-blind placebo-controlled trial medical

"This randomized double-blind placebo-controlled trial is being conducted at multiple sites"

A double-blind placebo-controlled trial is a study where participants are randomly given either a study treatment or a harmless look-alike, and neither the participants nor the researchers know who got which until the study ends. Like a blind taste test for a new product, this setup minimizes bias and produces more trustworthy evidence about whether a treatment really works and is safe—information that strongly influences regulatory approval, clinical adoption, and investor expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS)

Jaguar has received orphan drug designations for MVID & SBS in the US and EU

Jaguar has also completed enrollment of pediatric MVID patients in an ongoing randomized clinical trial with plans for an NDA filing in mid-2027

SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58^th Annual Meeting of ESPGHAN. These pediatric IF patients are receiving liquid oral crofelemer as an investigational drug under two separate investigator-initiated trials. One infant MVID IF patient is being treated with crofelemer as adjunctive therapy to parenteral support for more than 6 months and other pediatric patients with IF due to MVID and/or SBS received crofelemer adjunctive therapy for over 1 year together with reduced amounts of parenteral support (PS).

"We are pleased with these results for the safety and effectiveness of liquid oral crofelemer as adjunctive therapy to PS pediatric IF patients on life-sustaining PS. MVID is a congenital enteropathy and has a lethal natural history if not treated with life-sustaining and lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids. MVID is estimated to have a prevalence of approximately 200 patients, and to the best of our knowledge, crofelemer is being used to treat approximately 4% of the prevalent MVID patients, with the inclusion of additional MVID patients in an ongoing blinded study. Crofelemer has demonstrated reductions in parenteral support needs for IF patients with both MVID and SBS. Crofelemer has been well tolerated, and the pediatric IF patients are gaining weight and height, demonstrating reductions in their needs for PS, especially when adjusted for body weight. This is important because TPN is associated with significant comorbidities and reductions in PS needs are expected to improve clinical outcomes as well as quality of life measures for these pediatric IF patients," said Dr. Pravin Chaturvedi, Napo's Chief Scientific Officer and Chair of the company's Scientific Advisory Board.

Lisa Conte, the company's founder and CEO, said that "Crofelemer continues to have an impressive safety profile while demonstrating disease progression modification for the fragile pediatric IF patient population. The company has received interest and support from the parents of these IF patients, which has been heartening and inspirational."

Jaguar's family company, Napo Therapeutics S.P.A., is continuing to enroll adult patients with IF due to SBS using the same formulation of crofelemer. This randomized double-blind placebo-controlled trial is being conducted at multiple sites in Germany and Italy. An investigational study in adult SBS-IF patients is also being partially supported by the company in the US.

Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with serious toxicities to patients, including life-threatening infections, metabolic complications, liver and kidney function problems, reduction in normal growth parameters, cognitive functioning impacts among others.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jaguar Health (JAGX) announce about crofelemer at ESPGHAN on April 24, 2026?

Jaguar announced acceptance of two late-breaking abstracts on liquid oral crofelemer for pediatric IF. According to the company, abstracts cover MVID and SBS cases showing PS reductions and safety observations in treated children.

Has crofelemer shown clinical benefit for pediatric IF patients in Jaguar's reports?

Yes, reported benefits include reductions in parenteral support and gains in weight and height. According to the company, treated pediatric IF patients tolerated crofelemer and experienced decreases in PS needs when adjusted for body weight.

What regulatory designations does Jaguar have for crofelemer in MVID and SBS?

Jaguar has received orphan drug designations in both the US and the EU for MVID and SBS. According to the company, these designations apply to crofelemer for treating intestinal failure in these ultrarare conditions.

What is Jaguar's development timeline for pediatric MVID and a potential NDA?

Jaguar completed enrollment of pediatric MVID patients in a randomized trial and plans an NDA filing in mid-2027. According to the company, the ongoing blinded study includes additional MVID patients.

How widely is crofelemer currently used for MVID patients, according to Jaguar?

Crofelemer is being used in about 4% of the estimated ~200 prevalent MVID patients. According to the company, usage includes patients enrolled in ongoing clinical studies and investigator-initiated trials.